DOCSLIB.ORG

Drug Eruptions- When to Worry

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Eruptions- When to Worry 3/17/2017 Drug reactions: Drug Eruptions‐ When to Worry 3 things you need to know 1. Type of drug reaction 2. Statistics: – Which drugs are most likely to cause that type of Lindy P. Fox, MD reaction? Associate Professor 3. Timing: Director, Hospital Consultation Service – How long after the drug started did the reaction Department of Dermatology University of California, San Francisco begin? [email protected] I have no conflicts of interest to disclose 1 Drug Eruptions: Common Causes of Cutaneous Drug Degrees of Severity Eruptions • Antibiotics Simple Complex • NSAIDs Morbilliform drug eruption Drug hypersensitivity reaction Stevens-Johnson syndrome •Sulfa (SJS) Toxic epidermal necrolysis (TEN) • Allopurinol Minimal systemic symptoms Systemic involvement • Anticonvulsants Potentially life threatening 1 3/17/2017 Morbilliform (Simple) Drug Eruption Morbilliform (Simple) Drug Eruption Per the drug chart, the most likely culprit is: Per the drug chart, the most likely culprit is: Day Day Day ‐> ‐8 ‐7 ‐6 ‐5 ‐4 ‐3 ‐2 ‐1 0 1 Day ‐> ‐8 ‐7 ‐6 ‐5 ‐4 ‐3 ‐2 ‐1 0 1 A vancomycin x x x x A vancomycin x x x x B metronidazole x x B metronidazole x x C ceftriaxone x x x C ceftriaxone x x x D norepinephrine x x x D norepinephrine x x x E omeprazole x x x x E omeprazole x x x x F SQ heparin x x x x F SQ heparin x x x x trimethoprim/ trimethoprim/ G xxxxxxx G xxxxxxx sulfamethoxazole sulfamethoxazole Admit day Rash onset Admit day Rash onset Morbilliform (Simple) Drug Eruption Drug Induced Hypersensitivity Syndrome • Begins 5‐10 days after drug started • Skin eruption associated with systemic symptoms and • Erythematous macules, papules alteration of internal organ function • Pruritus • “DRESS”‐ Drug reaction w/ eosinophilia and systemic • No systemic symptoms symptoms • Risk factors: EBV, HIV infection • “DIHS”= Drug induced hypersensitivity syndrome • Treatment: • Begins 2‐ 6 weeks after medication started – D/C medication – time to abnormally metabolize the medication – diphenhydramine, topical steroids • Resolves 7‐10 days after drug stopped • Role for viral reactivation, esp HHV6 – Gets worse before gets better • Mortality 10% 2 3/17/2017 Hypersensitivity Reactions Drug Induced Hypersensitivity Syndrome Drugs • Aromatic anticonvulsants • Each class of drug causes a slightly different clinical picture – phenobarbital, carbamazepine, phenytoin • Facial edema characteristic of all – THESE CROSS‐REACT • Anticonvulsants: • Sulfonamides – 3 weeks • Lamotrigine – Atypical lymphocytosis, hepatic failure • Dapsone • Dapsone: • Allopurinol (HLA‐B*5801) – 6 weeks • NSAIDs – No eosinophilia • Other • Allopurinol: – Abacavir (HLA‐ B*5701) – 7 weeks – Nevirapine (HLA‐DRB1*0101) – Elderly patient on thiazide diuretic – Minocycline, metronidazole, azathioprine, gold salts – Renal failure – Requires steroid sparing agent to treat (avoid azathioprine) • Each class of drug causes a slightly different clinical picture DIHS‐ Clinical Features Hypersensitivity Reactions Treatment • Rash • Stop the medication – FACIAL EDEMA • Follow CBC with diff, LFT’s, BUN/Cr • Fever (precedes eruption by day or more) • Avoid cross reacting medications!!!! • Pharyngitis – Aromatic anticonvulsants cross react (70%) • Hepatitis • Phenobarbital, Phenytoin, Carbamazepine • Arthralgias • Valproic acid and Keppra generally safe • Lymphadenopathy • Systemic steroids (Prednisone 1.5‐2mg/kg) • Hematologic abnormalities – Taper slowly‐ 1‐3 months – eosinophilia – atypical lymphocytosis • Allopurinol hypersensitivity may require steroid • Other organs involved sparing agent • NOT azathioprine (also metabolized by xanthine oxidase) – Interstitial pneumonitis, interstitial nephritis, thyroiditis – Myocarditis‐ acute eosinophilic mycocarditis or acute necrotizing • Completely recover, IF the hepatitis resolves eosinophilic myocarditis • Check TSH monthly for 6 months • EKG, echocardiogram, cardiac enzymes • Watch for later cardiac involvement (low EF) 3 3/17/2017 Consult: 2 days of redness, pustules, Acute generalized exanthematous pustulosis neutrophilia on azithromycin for bronchitis Clinical Features • Acute onset • Fever, neutrophilia • Edema (face, hands) • Additional morphologies – purpura, vesicles, bullae, erythema multiforme‐like lesions • Mucous membrane lesions! • May mimic pustular psoriasis • Typically resolves within 2 weeks of stopping medication, but may require systemic steroids Acute Generalized Exanthematous Consult: 5 days of painful red lesion Pustulosis = Pustular Drug Eruption after taking tylenol for headache • EuroSCAR (97 cases of AGEP, 1009 controls): – Macrolides – Ampicillin/amoxicillin BJD 2007 Nov;157(5):989-96. – Quinolones – (hydroxy)chloroquine – Sulphonamides – Terbinafine – Diltiazem – No infections found – Not associated with personal or family history of psoriasis •Mercury • Enterovirus infection Amantadine 4 3/17/2017 Consult: Blisters after starting Fixed Drug Eruption vancomycin • Morphology – Annular red plaque – Can have central bulla – Heals with marked hyperpigmentation • Pain is the major symptom • Limited number of lesions • “Fixed” is a curious phenomenon – if patient takes the same medication again, the same spots light up • Spontaneously resolves Drug-Induced Linear IgA Disease Drug-Induced Linear IgA Disease • Immune-mediated subepidermal blistering disease Common causes • Others – Antigen: 97 kDa of BPAG2 (BP180) – Vancomycin – Amiodarone – DIF: band-like (linear) IgA deposition at DEJ – Penicillins – Sulfamethoxazole – Cephalosporins – Diclofenac • Clinical features – Captopril – Furosemide – Subepidermal blisters accentuated in flexural areas – Glyburide – Morphology: herpetiform or rosette-like –GCSF • Can be caused by medications –IFN – Vancomycin most common – Lithium • Spontaneously resolves after stopping medication in – Phenytoin – Piroxicam most cases – Rifampin 5 3/17/2017 Consult: My skin hurts and is blistering Severe Bullous Reactions • Stevens‐Johnson Syndrome • Toxic Epidermal Necrolysis (TEN) Stevens-Johnson Syndrome (SJS) and Toxic Stevens-Johnson (SJS) versus Epidermal Necrolysis (TEN) Toxic Epidermal Necrolysis (TEN) • Medications Disease BSA – Sulfonamides – Aromatic anticonvulsants (carbamazapine [HLA‐ SJS < 10% B*1502], phenobarbital, phenytoin) – Allopurinol (HLA‐B*5801) SJS/TEN overlap 10-30% – NSAIDs (esp Oxicams) – Nevirapine (HLA‐DRB1*0101) TEN with spots > 30% – Lamotrigine – Weaker link: Sertraline, Pantoprazole, Tramadol TEN without spots Sheets of epidermal loss > 10% J Invest Dermatol. 2008 Jan;128(1):35‐44 6 3/17/2017 Stevens-Johnson (SJS) versus Toxic Epidermal Necrolysis (TEN) Question 2 SJS TEN What is the most important consult besides Atypical targets Erythema, bullae dermatology to get in a patient with Mucosal Skin pain SJS/TEN? membranes ≥ 2 Mucosal A. Renal membranes ≥ 2 B. Ophthalmology Causes: Causes: C. Allergy/immunology Drugs Drugs D. Wound care Mycoplasma E. GI/liver HSV Question 2 SJS/TEN: Emergency Management What is the most important consult besides • Stop all unnecessary medications dermatology to get in a patient with – The major predictor of survival and severity of disease SJS/TEN? • Ophthalmology consult • Check for Mycoplasma‐ 25% of SJS in pediatric patients A. Renal • Treat like a burn patient B. Ophthalmology – Monitor fluid and electrolyte status (but don’t overhydrate) C. Allergy/immunology – Nutritional support D. Wound care – Warm environment – Respiratory care E. GI/liver • Death (up to 25% of patients with more than 30% skin loss, age dependent) 7 3/17/2017 SJS/TEN: Treatment • Topical – Protect exposed skin, prevent secondary infection – Aquaphor and Vaseline gauze • Systemic‐ controversial – No role for empiric antibiotics • Surveillance cultures • Treat secondary infection (septicemia) – Consider antivirals, treat Mycoplasma if present – SJS: high dose corticosteroids ‐1.5‐2 mg/kg prednisone (no RCT) – TEN: IVIG 1g/kg/d x 4d – TNF blockade, cyclosporine 8.
Load more

Recommended publications
  • Generalized Edema Resulting from Mixed Intestinal Infection by Entamoebia Histolytica and E
    Case Report JOJ Case Stud Volume 12 Issue 2 -April 2021 Copyright © All rights are reserved by Ajite Adebukola DOI: 10.19080/JOJCS.2021.12.555833 Generalized Edema Resulting from Mixed Intestinal Infection by Entamoebia Histolytica and E. Coli in a Nigerian Female Adolescent: A Case Report Ajite Adebukola1,2*, Oluwayemi Oludare1,2 and Fatunla Odunayo2 1Department of Paediatrics, Ekiti State University, Nigeria 2Department of Paediatrics, Ekiti State University Teaching Hospital, Nigeria Submission: March 15, 2021; Published: April 08, 2021 *Corresponding author: Ajite Adebukola, Consultant Paediatrician, Department of Paediatrics, Ekiti State University, Ado Ekiti, Nigeria Abstract Amoebiasis, a clinical condition caused by Entamoeba histolytica does not usually present with generalized oedema known as anarsarca. We present a case of an adolescent female Nigerian who was admitted on account of chronic diarrhea and anarsarca in a tertiary hospital, Southwest Nigeria. There was no proteinuria. She however had cyst of E. histolytica and growth of E. coli in her stool; she also had E. coli isolated in her urine. She had hypoproteinaemia (35.2g/L) and hypoalbuminaemia (21.3g/L) as well as hypokalemia (2.97mmol/L). Symptoms resolved Entamoeba histolytica and Escherichia coli bacteria may be responsible for the worse clinical manifestations of Amoebiasis and biochemical parameters normalized following treatment with Nitrofurantoin, Tinidazole and Ciprofloxacin. A mixed infection of Keywords: Amoebiasis; Chronic diarrhea; Hypoproteinaemia; Anasarca Introduction Amoebiasis, caused by the protozoan Entamoeba histolytica of amenorrhoea. is an infection that frequently manifests clinically with symptoms recurrent generalized body swelling, and a seven-month history of abdominal pain, diarrhoea, dysentery and weight loss [1,2].
    [Show full text]
  • Ehrlichiosis and Anaplasmosis Are Tick-Borne Diseases Caused by Obligate Anaplasmosis: Intracellular Bacteria in the Genera Ehrlichia and Anaplasma
    Ehrlichiosis and Importance Ehrlichiosis and anaplasmosis are tick-borne diseases caused by obligate Anaplasmosis: intracellular bacteria in the genera Ehrlichia and Anaplasma. These organisms are widespread in nature; the reservoir hosts include numerous wild animals, as well as Zoonotic Species some domesticated species. For many years, Ehrlichia and Anaplasma species have been known to cause illness in pets and livestock. The consequences of exposure vary Canine Monocytic Ehrlichiosis, from asymptomatic infections to severe, potentially fatal illness. Some organisms Canine Hemorrhagic Fever, have also been recognized as human pathogens since the 1980s and 1990s. Tropical Canine Pancytopenia, Etiology Tracker Dog Disease, Ehrlichiosis and anaplasmosis are caused by members of the genera Ehrlichia Canine Tick Typhus, and Anaplasma, respectively. Both genera contain small, pleomorphic, Gram negative, Nairobi Bleeding Disorder, obligate intracellular organisms, and belong to the family Anaplasmataceae, order Canine Granulocytic Ehrlichiosis, Rickettsiales. They are classified as α-proteobacteria. A number of Ehrlichia and Canine Granulocytic Anaplasmosis, Anaplasma species affect animals. A limited number of these organisms have also Equine Granulocytic Ehrlichiosis, been identified in people. Equine Granulocytic Anaplasmosis, Recent changes in taxonomy can make the nomenclature of the Anaplasmataceae Tick-borne Fever, and their diseases somewhat confusing. At one time, ehrlichiosis was a group of Pasture Fever, diseases caused by organisms that mostly replicated in membrane-bound cytoplasmic Human Monocytic Ehrlichiosis, vacuoles of leukocytes, and belonged to the genus Ehrlichia, tribe Ehrlichieae and Human Granulocytic Anaplasmosis, family Rickettsiaceae. The names of the diseases were often based on the host Human Granulocytic Ehrlichiosis, species, together with type of leukocyte most often infected.
    [Show full text]
  • Concurrent Beau Lines, Onychomadesis, and Retronychia Following Scurvy
    CASE REPORT Concurrent Beau Lines, Onychomadesis, and Retronychia Following Scurvy Dayoung Ko, BS; Shari R. Lipner, MD, PhD the proximal nail plate from the distal nail plate leading to shedding of the nail. It occurs due to a complete growth PRACTICE POINTS arrest in the nail matrix and is thought to be on a con- • Beau lines, onychomadesis, and retronychia are nail tinuum with Beau lines. The etiologies of these 2 condi- conditions with distinct clinical findings. tions overlap and include trauma, inflammatory diseases, • Beau lines and onychomadesis may be seen 1-5 concurrently following trauma, inflammatory dis- systemic illnesses, hereditary conditions, and infections. eases, systemic illnesses, hereditary conditions, In almost all cases of both conditions, normal nail plate and infections. production ensues upon identification and removal of the 3,4,6 • Retronychia shares a common pathophysiology inciting agent or recuperation from the causal illness. with Beau lines and onychomadesis, and all reflect Beau lines will move distally as the nail grows out and slowing or cessation of nail plate production. can be clipped. In onychomadesis, the affected nails will be shed with time. Resolution of these nail defects can be estimated from average nail growth rates (1 mm/mo for fingernails and 2–3 mm/mo for toenails).7 Beau lines, onychomadesis, and retronychia are nail conditions with Retronychia is defined as a proximal ingrowing of their own characteristic clinical findings. It has been hypothesized the nail plate into the ventral surface of the proximal nail that these 3 disorders may share a common pathophysiologic fold.4,6 It is thought to occur via vertical progression of mechanism of slowing and/or halting nail plate production at the the nail plate into the proximal nail fold, repetitive nail nail matrix.
    [Show full text]
  • ORIGINAL ARTICLE a Clinical and Histopathological Study of Lichenoid Eruption of Skin in Two Tertiary Care Hospitals of Dhaka
    ORIGINAL ARTICLE A Clinical and Histopathological study of Lichenoid Eruption of Skin in Two Tertiary Care Hospitals of Dhaka. Khaled A1, Banu SG 2, Kamal M 3, Manzoor J 4, Nasir TA 5 Introduction studies from other countries. Skin diseases manifested by lichenoid eruption, With this background, this present study was is common in our country. Patients usually undertaken to know the clinical and attend the skin disease clinic in advanced stage histopathological pattern of lichenoid eruption, of disease because of improper treatment due to age and sex distribution of the diseases and to difficulties in differentiation of myriads of well assess the clinical diagnostic accuracy by established diseases which present as lichenoid histopathology. eruption. When we call a clinical eruption lichenoid, we Materials and Method usually mean it resembles lichen planus1, the A total of 134 cases were included in this study prototype of this group of disease. The term and these cases were collected from lichenoid used clinically to describe a flat Bangabandhu Sheikh Mujib Medical University topped, shiny papular eruption resembling 2 (Jan 2003 to Feb 2005) and Apollo Hospitals lichen planus. Histopathologically these Dhaka (Oct 2006 to May 2008), both of these are diseases show lichenoid tissue reaction. The large tertiary care hospitals in Dhaka. Biopsy lichenoid tissue reaction is characterized by specimen from patients of all age group having epidermal basal cell damage that is intimately lichenoid eruption was included in this study. associated with massive infiltration of T cells in 3 Detailed clinical history including age, sex, upper dermis. distribution of lesions, presence of itching, The spectrum of clinical diseases related to exacerbating factors, drug history, family history lichenoid tissue reaction is wider and usually and any systemic manifestation were noted.
    [Show full text]
  • How to Recognize a Suspected Cardiac Defect in the Neonate
    Neonatal Nursing Education Brief: How to Recognize a Suspected Cardiac Defect in the Neonate https://www.seattlechildrens.org/healthcare- professionals/education/continuing-medical-nursing-education/neonatal- nursing-education-briefs/ Cardiac defects are commonly seen and are the leading cause of death in the neonate. Prompt suspicion and recognition of congenital heart defects can improve outcomes. An ECHO is not needed to make a diagnosis. Cardiac defects, congenital heart defects, NICU, cardiac assessment How to Recognize a Suspected Cardiac Defect in the Neonate Purpose and Goal: CNEP # 2092 • Understand the signs of congenital heart defects in the neonate. • Learn to recognize and detect heart defects in the neonate. None of the planners, faculty or content specialists has any conflict of interest or will be presenting any off-label product use. This presentation has no commercial support or sponsorship, nor is it co-sponsored. Requirements for successful completion: • Successfully complete the post-test • Complete the evaluation form Date • December 2018 – December 2020 Learning Objectives • Describe the risk factors for congenital heart defects. • Describe the clinical features of suspected heart defects. • Identify 2 approaches for recognizing congenital heart defects. Introduction • Congenital heart defects may be seen at birth • They are the most common congenital defect • They are the leading cause of neonatal death • Many neonates present with symptoms at birth • Some may present after discharge • Early recognition of CHD
    [Show full text]
  • Truncal Rashes Stan L
    Healthy Baby Practical advice for treating newborns and toddlers. Getting Truculent with Truncal Rashes Stan L. Block, MD, FAAP A B C All images courtesy of Stan L. Block, MD, FAAP. Figure 1. Afebrile 22-month-old white male presents to your office with this slowly spreading, somewhat generalized, and refractory truncal rash for the past 4 weeks. It initially started on the right side of his trunk (A) and later extended down his right upper thigh (B). The rash has now spread to the contralateral side on his back (C), and is most confluent and thickest over his right lateral ribs. n a daily basis, we pediatricians would not be readily able to identify this rash initially began on the right side of his encounter a multitude of rashes relatively newly described truncal rash trunk (see Figure 1A) and then extended O of varied appearance in children shown in some of the following cases. distally down to his right upper thigh (see of all ages. Most of us gently-seasoned As is typical, certain clues are critical, Figure 1B). Although the rash is now dis- clinicians have seen nearly all versions including the child’s age, the duration tributed over most of his back (see Figure of these “typical” rashes. Yet, I venture and the distribution of the rash. Several 1C), it is most confluent and most dense to guess that many practitioners, who of these rashes notably mimic more com- over his right lateral ribs. would be in good company with some of mon etiologies, as discussed in some of From Figure 1, you could speculate my quite erudite partners (whom I asked), the following cases.
    [Show full text]
  • Cutaneous Manifestations of Abdominal Arteriovenous Fistulas
    Cutaneous Manifestations of Abdominal Arteriovenous Fistulas Jessica Scruggs, MD; Daniel D. Bennett, MD Abdominal arteriovenous (A-V) fistulas may be edema.1-3 We report a case of abdominal aortocaval spontaneous or secondary to trauma. The clini- fistula presenting with lower extremity edema, ery- cal manifestations of abdominal A-V fistulas are thema, and cyanosis that had been previously diag- variable, but cutaneous findings are common and nosed as venous stasis dermatitis. may be suggestive of the diagnosis. Cutaneous physical examination findings consistent with Case Report abdominal A-V fistula include lower extremity A 51-year-old woman presented to the emergency edema with cyanosis, pulsatile varicose veins, department with worsening lower extremity swelling, and scrotal edema. redness, and pain. Her medical history included a We present a patient admitted to the hospital diagnosis of congestive heart failure, chronic obstruc- with lower extremity swelling, discoloration, and tive pulmonary disease, hepatitis C virus, tobacco pain, as well as renal insufficiency. During a prior abuse, and polysubstance dependence. Swelling, red- hospitalization she was diagnosed with venous ness, and pain of her legs developed several years stasis dermatitis; however, CUTISher physical examina- prior, and during a prior hospitalization she had been tion findings were not consistent with that diagno- diagnosed with chronic venous stasis dermatitis as sis. Imaging studies identified and characterized well as neurodermatitis. an abdominal aortocaval fistula. We propose that On admission, the patient had cool lower extremi- dermatologists add abdominal A-V fistula to the ties associated with discoloration and many crusted differential diagnosis of patients presenting with ulcerations. Aside from obesity, her abdominal exam- lower extremity edema with cyanosis, and we ination was unremarkable and no bruits were noted.
    [Show full text]
  • Tips for Managing Treatment-Related Rash and Dry Skin
    RASH Tips for Managing Treatment-Related Rash and Dry Skin Presented by Stewart B. Fleishman, MD Continuum Cancer Centers of New York: Beth Israel & St. Luke’s-Roosevelt Lindy P. Fox, MD University of California San Francisco David H. Garfield, MD University of Colorado Comprehensive Cancer Center Carol S. Viele, RN, MS University of California San Francisco Carolyn Messner, DSW CancerCare Learn about: • Effects of targeted treatments on the skin • Managing rashes and dry skin • Treating nail conditions • Your support team Help and Hope CancerCare is a national nonprofit organization that provides free support services to anyone affected by cancer: people with cancer, caregivers, children, loved ones, and the bereaved. CancerCare programs—including counseling and support groups, education, financial assistance, and practical help—are provided by professional oncology social workers and are completely free of charge. Founded in 1944, CancerCare provided individual help to more than 100,000 people last year and had more than 1 million unique visitors to our websites. For more information, call 1-800-813-HOPE (4673) or visit www.cancercare.org. Contacting CancerCare National Office Administration CancerCare Tel: 212-712-8400 The material presented in this patient booklet is provided for your general 275 Seventh Avenue Fax: 212-712-8495 information only. It is not intended as medical advice and should not be relied New York, NY 10001 Email: [email protected] upon as a substitute for consultations with qualified health professionals who Email: [email protected] Website: www.cancercare.org are aware of your specific situation. We encourage you to take information and Services questions back to your individual health care provider as a way of creating a Tel: 212-712-8080 dialogue and partnership about your cancer and your treatment.
    [Show full text]
  • Pedal Edema in Older Adults Jennifer M
    www.aging.arizona.edu July 2013 (updated May2015) ELDER CARE A Resource for Interprofessional Providers Pedal Edema in Older Adults Jennifer M. Vesely, MD, Teresa Quinn, MD, and Donald Pine, MD, Family Medicine Residency, University of Minnesota Pedal edema is the accumulation of fluid in the feet and pedal edema, which is more common in older adults, is lower legs. It is typically caused by one of two mechanisms. often multifactorial and may reflect a systemic process. The first is venous edema, caused by increased capillary Treating the underlying cause can often lessen the edema. filtration and retention of protein-poor fluid from the Table 1 lists common and less common causes of bilateral venous system into the interstitial space. The other pedal edema. mechanism is lymphatic edema, caused by obstruction or In addition to seeking evidence for the conditions listed in dysfunction of lymphatic outflow from the legs resulting in Table 1, certain clues in the patient’s presentation might accumulation of protein-rich interstitial fluid. These two point to a particular cause of edema. In particular, the mechanisms can operate independently or together. duration of edema and presence of pain should be noted. Regardless of the mechanism, chronic bilateral pedal Acute onset and presence of edema for less than 72 hours edema is detrimental to the health and quality of life of suggests the possibility of venous thrombosis and steps older adults. Besides alterations in cosmetic appearance or should be taken to exclude that diagnosis. Edema due to the discomfort it may cause, older adults with pedal edema chronic venous insufficiency is often associated with a dull often experience gait disturbance with decreased mobility aching pain.
    [Show full text]
  • Review of Systems Health History Sheet Patient: ______DOB: ______Age: ______Gender: M / F
    603 28 1/4 Road Grand Junction, CO 81506 (970) 263-2600 Review of Systems Health History Sheet Patient: _________________ DOB: ____________ Age: ______ Gender: M / F Please mark any symptoms you are experiencing that are related to your complaint today: Allergic/ Immunologic Ears/Nose/Mouth/Throat Genitourinary Men Only Frequent Sneezing Bleeding Gums Pain with Urinating Pain/Lump in Testicle Hives Difficulty Hearing Blood in Urine Penile Itching, Itching Dizziness Difficulty Urinating Burning or Discharge Runny Nose Dry Mouth Incomplete Emptying Problems Stopping or Sinus Pressure Ear Pain Urinary Frequency Starting Urine Stream Cardiovascular Frequent Infections Loss of Urinary Control Waking to Urinate at Chest Pressure/Pain Frequent Nosebleeds Hematologic / Lymphatic Night Chest Pain on Exertion Hoarseness Easy Bruising / Bleeding Sexual Problems / Irregular Heart Beats Mouth Breathing Swollen Glands Concerns Lightheaded Mouth Ulcers Integumentary (Skin) History of Sexually Swelling (Edema) Nose/Sinus Problems Changes in Moles Transmitted Diseases Shortness of Breath Ringing in Ears Dry Skin Women Only When Lying Down Endocrine Eczema Bleeding Between Shortness of Breath Increased Thirst / Growth / Lesions Periods When Walking Urination Itching Heavy Periods Constitutional Heat/Cold Intolerance Jaundice (Yellow Extreme Menstrual Pain Exercise Intolerance Gastrointestinal Skin or Eyes) Vaginal Itching, Fatigue Abdominal Pain Rash Burning or Discharge Fever Black / Tarry Stool Respiratory Waking to Urinate at Weight Gain (___lbs) Blood
    [Show full text]
  • Psoriasiform Drug Eruption Induced by Anti-Tuberculosis Medication: Potential Role of Plasma­ Cytoid Dendritic Cells
    Letters to the Editor 305 Psoriasiform Drug Eruption Induced by Anti-tuberculosis Medication: Potential Role of Plasma- cytoid Dendritic Cells Jae-Jeong Park1, Yoo Duk Choi2, Jee-Bum Lee1, Seong-Jin Kim1, Seung-Chul Lee1, Young Ho Won1 and Sook Jung Yun1* Departments of 1Dermatology and 2Pathology, Chonnam National University Medical School, 8 Hak-Dong, Dong-Gu, Gwangju, 501-757, Korea. *E mail: [email protected] Accepted November 23, 2009. Psoriasiform drug eruptions can be induced by several one month earlier, and treated with bicalutamide and tamsulosin drugs (1). Psoriasis is a chronic inflammatory disease hydrochloride, which were started one week after the skin eruption began. The skin lesions spread from his arms to the trunk and lower characterized by T-cell-mediated cytokine production extremities. On physical examination, erythematous papulosqua- that drives the hyperproliferation and abnormal differen- mous lesions were found, scattered on his trunk, arms, hands, legs, tiation of keratinocytes (2). Drugs can cause new lesions and buttocks (Fig. 1). Other than an elevated eosinophil count (731/ when there is no history or family history of psoriasis. mm3, normal range 0–483/mm3; 10.6%, normal range 0–7%) and Based on the psoriatic drug eruption probability score, IgE level (361 IU/ml, normal range 0–100 IU/ml), the laboratory findings were within normal limits, including a complete blood β‑blockers, synthetic anti‑malaria drugs, non‑steroidal cell count, liver and renal function tests, and urinalysis. Syphilis anti‑inflammatory drugs (NSAIDs), lithium, digoxin, and Venereal Disease Research Laboratory (VDRL) and Treponema tetracycline antibiotics are relevant in psoriasis (1, 3–5).
    [Show full text]
  • Drug Eruptions
    DRUG ERUPTIONS http://www.aocd.org A drug eruption is an adverse skin reaction to a drug. Many medications can cause reactions, especially antimicrobial agents, sulfa drugs, NSAIDs, chemotherapy agents, anticonvulsants, and psychotropic drugs. Drug eruptions can imitate a variety of other skin conditions and therefore should be considered in any patient taking medications or that has changed medications. The onset of drug eruptions is usually within 2 weeks of beginning a new drug or within days if it is due to re-exposure to a certain drug. Itching is the most common symptom. Drug eruptions occur in approximately 2-5% of hospitalized patients and in greater than 1% of the outpatient population. Adverse reactions to drugs are more prevalent in women, in the elderly, and in immunocompromised patients. Drug eruptions may be immunologically or non-immunologically mediated. There are 4 types of immunologically mediated reactions, with Type IV being the most common. Type I is immunoglobulin-E dependent and can result in anaphylaxis, angioedema, and urticaria. Type II is cytotoxic and can result in purpura. Type III reactions are immune complex reactions which can result in vasculitis and type IV is a delayed-type reaction which results in contact dermatitis and photoallergic reactions. This is important as different medications are associated with different types of reactions. For example, insulin is related with type I reactions whereas penicillin, cephalosporins, and sulfonamides cause type II reactions. Quinines and salicylates can cause type III reactions and topical medications such as neomycin can cause type IV reactions. The most common drugs that may potentially cause drug eruptions include amoxicillin, trimethoprim sulfamethoxazole, ampicillin, penicillin, cephalosporins, quinidine and gentamicin sulfate.
    [Show full text]